<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184453</url>
  </required_header>
  <id_info>
    <org_study_id>MRCTA,ECFAH of FMU [2019]252</org_study_id>
    <nct_id>NCT04184453</nct_id>
  </id_info>
  <brief_title>Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients</brief_title>
  <official_title>Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aceruloplasminemia is an autosomal recessive disorder characterized by iron deposition in the
      brain and visceral organs. Deferiprone was used to treat aceruloplasminemia in previous
      study. In this study, we will assess the clinical curative effect evaluation of oral
      deferiprone in Chinese aceruloplasminemia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is one of the most severe symptom in aceruloplasminemia. In this study, we use R2*
      of pancreas MRI to evaluate the effect of deferiprone treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">November 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients who was diagnosed as aceruloplasminiaemia</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pancreas MRI</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Pancreas MRI is related to iron accumulation of pancreas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of glycated hemoglobin (HbA1c)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>HbA1c is a measure of long-term blood sugar control</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Aceruloplasminemia</condition>
  <arm_group>
    <arm_group_label>Deferiprone treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferiprone (25 mg/kg/day) was given to the enrolled patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone treated</intervention_name>
    <description>Deferiprone (25 mg/kg/day) was given to the enrolled patients.</description>
    <arm_group_label>Deferiprone treated</arm_group_label>
    <other_name>Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years

          -  Diagnosed with aceruloplasminaemia

          -  Genetically confirmed diagnosis of aceruloplasminaemia

        Exclusion Criteria:

          -  Contraindications to deferiprone therapy

          -  Pregnancy was excluded in women of childbearing age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanjin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology , First Affiliated Hospital Fujian Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin He</last_name>
    <phone>13645050186</phone>
    <email>hejin@fjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanjin Chen</last_name>
    <phone>13860601359</phone>
    <phone_ext>059187982772</phone_ext>
    <email>wanjinchen75@fjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology , First Affiliated Hospital Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HeJin</last_name>
      <phone>13645050186</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Wan-Jin Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aceruloplasminemia</keyword>
  <keyword>Deferiprone</keyword>
  <keyword>Pancreas MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Iron Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

